Literature DB >> 7519854

Involvement of membrane bleomycin-binding sites in bleomycin cytotoxicity.

G Pron1, J Belehradek, S Orlowski, L M Mir.   

Abstract

The authors have recently shown the existence of bleomycin (BLM)-binding sites at the surface of DC-3F cells. In order to study the involvement of these sites in the sensitivity of the cells to bleomycin several BLM-resistant cell lines from DC-3F cells were analysed. These mutants were obtained by electrotransfection of the Sh ble gene (D/BlmI cells) or the Sh ble-beta Gal fusion gene (D/BlmII cells) and/or by continuous culture in the presence of BLM (D/BlmIR and D/Blm40 cells). The resistance levels of the D/BlmII and D/Blm40 cells were 50- and 22-fold, respectively, determined at the EC50 level. The D/BlmI cells were only 2-fold resistant, whereas D/BlmIR cells were so resistant that almost no cytotoxicity was detected up to 200 microM BLM external concentration. Electropermeabilization was used in an attempt to bypass the plasma membrane of the cells and permit the distinction between internal resistance and membrane resistance. The former was observed when the products of the transfected genes were present. With respect to membrane resistance, differences were detected in the number of BLM-binding sites in several mutant cell lines, which could account for the differences in cell sensitivity to BLM. This suggests that the BLM-binding sites found at the cell surface may play a crucial role in BLM internalization and consequently in its cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519854     DOI: 10.1016/0006-2952(94)90101-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Comparative roles of the cell wall and cell membrane in limiting uptake of xenobiotic molecules by Saccharomyces cerevisiae.

Authors:  Mustapha Aouida; Omar Tounekti; Omrane Belhadj; Lluis M Mir
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 2.  Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.

Authors:  Claudia M Hattinger; Serena Vella; Elisa Tavanti; Marilù Fanelli; Piero Picci; Massimo Serra
Journal:  Pharmacogenomics       Date:  2016-11-24       Impact factor: 2.533

3.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

4.  Isolation and characterization of Saccharomyces cerevisiae mutants with enhanced resistance to the anticancer drug bleomycin.

Authors:  Mustapha Aouida; Omar Tounekti; Anick Leduc; Omrane Belhadj; Lluis Mir; Dindial Ramotar
Journal:  Curr Genet       Date:  2004-03-09       Impact factor: 3.886

5.  Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy.

Authors:  L M Mir; L F Glass; G Sersa; J Teissié; C Domenge; D Miklavcic; M J Jaroszeski; S Orlowski; D S Reintgen; Z Rudolf; M Belehradek; R Gilbert; M P Rols; J Belehradek; J M Bachaud; R DeConti; B Stabuc; M Cemazar; P Coninx; R Heller
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

6.  Electrochemotherapy on liver tumours in rabbits.

Authors:  L H Ramirez; S Orlowski; D An; G Bindoula; R Dzodic; P Ardouin; C Bognel; J Belehradek; J N Munck; L M Mir
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

7.  Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis.

Authors:  Qi Wang; Kangping Cui; Osvaldo Espin-Garcia; Dangxiao Cheng; Xiaoping Qiu; Zhuo Chen; Malcolm Moore; Robert G Bristow; Wei Xu; Sandy Der; Geoffrey Liu
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

8.  Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells.

Authors:  Christophe Y Calvet; Delphine Famin; Franck M André; Lluis M Mir
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

9.  Pingyangmycin inhibits glycosaminoglycan sulphation in both cancer cells and tumour tissues.

Authors:  Ying Lan; Xiulian Li; Yong Liu; Yanli He; Cui Hao; Hua Wang; Liying Jin; Guoqing Zhang; Shufeng Zhang; Aimin Zhou; Lijuan Zhang
Journal:  J Cell Mol Med       Date:  2020-02-18       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.